DNA 8.92 Ginkgo Bioworks Holdings, Inc.
| Range: | 5.26-75.2 | Vol Avg: | 1493890 | Last Div: | 0 | Changes: | 0.15 |
| Beta: | 1.1 | Cap: | 0.41B | Currency: | USD | Exchange: | NYSE |
| Sector: | Healthcare | IPO: | Mon Apr 19 2021 | Empoloyees: | 1218 | ||
| CUSIP: | 37611X100 | CIK: | 0001830214 | ISIN: | US37611X1000 | Country: | US |
| CEO: | Dr. Jason Kelly | Website: | https://www.ginkgobioworks.com | ||||
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Stock Details
Positive 0.13
Pet DNA Testing Market Report 2024: Industry Analysis and Forecast (2018-2030) with Share & Strategy Insights of Leading Players - Zoetis (Basepaws), Mars Petcare (Wisdom Panel), Orivet Genetic Pet Care & More
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Pet DNA Testing Market Size, Share and Tren...
globenewswire.com·Tue Oct 15 2024
Positive 0.20
KBRA Assigns Preliminary Ratings to Freddie Mac's STACR 2024-DNA3
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 cl...
businesswire.com·Thu Oct 03 2024
Positive 0.40
Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA
OAKLAND, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the Unite...
globenewswire.com·Wed Sep 18 2024
Positive 0.28
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid m...
accesswire.com·Tue Sep 17 2024
Negative -0.41
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
Companies will jointly research DNA-damage response kinase targets to identify potential d...
globenewswire.com·Tue Sep 17 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow